We therefore hypothesized that a B2R-antagonist like icatibant, an approved compound for the treatment of hereditary angioedema [39], counter-regulates the effects of bradykinin during a SARS-CoV-2-infection and thereby has a protective effect on the integrity of the airway mucosa. Here, BDKRB2 is linked to hereditary angioedema.